|drug2172||Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet Wiki||1.00|
|drug3947||Telmisartan 40Mg Oral Tablet Wiki||1.00|
|drug387||Atorvastatin 20 Mg Oral Tablet Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Post-discharge rehabilitation regimens for covid-19 patients have not been supported by high-quality evidence-based medical evidence.The first part of this study is a cross-sectional study.The contents of the study were the factors related to the dysfunction of COVID - 19 patients after discharge from the hospital in Wuhan.The second part of this study is a cohort study.To observe the functional changes of COVID-19 patients after discharge in hospital rehabilitation, home rehabilitation and no rehabilitation, in order to propose a more safe and effective rehabilitation program.
Description: To take a history and physical examinationMeasure: Symptoms and signs Time: Ten days
Description: To take a physical examination and mMRCMeasure: Respiratory function Time: Ten days
Description: To take a MMT, 6-min walking test and Borg IndexMeasure: The body function Time: Ten days
Description: To take a modified Barthel indexMeasure: ADL Time: Ten days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports